Isolated Nonvisualization of the Fetal Gallbladder Should Be Considered for the Prenatal Diagnosis of Cystic Fibrosis.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2019
Historique:
received: 08 01 2018
accepted: 11 04 2018
pubmed: 20 6 2018
medline: 18 12 2019
entrez: 20 6 2018
Statut: ppublish

Résumé

Cystic fibrosis (CF) can be revealed during fetal life by diverse ultrasound digestive abnormalities (USDA) such as fetal echogenic bowel or fetal intestinal loop dilatation, nonvisualization of the fetal gallbladder (NVFGB) being rarely observed in isolation. Only 6 cases of CF revealed by isolated NVFGB have been reported so far in the literature. Furthermore, recent studies suggested that this sign is of poor predictive value for CF. We report on the results of a 6-year French tricenter study on 1,124 cases of fetal USDA for whom a comprehensive molecular study was performed for CF. Among the 37 CF fetuses, 5 (13.5%) presented with isolated NVFGB at ultrasound (US) examination at 24-31 weeks of gestation. This sign was more frequently observed in CF fetuses than in non-CF fetuses, with a likelihood ratio of 2.7. The genotypes included three c.1521_1523del (F508del) homozygous cases and two compound heterozygous cases for a frequent and a rare CF-causing variant. These observations highlight the importance to report on the presence and aspect of the fetal gallbladder at the second trimester US scan and to consider prenatal CFTR molecular analysis in cases of isolated NVFGB.

Sections du résumé

BACKGROUND BACKGROUND
Cystic fibrosis (CF) can be revealed during fetal life by diverse ultrasound digestive abnormalities (USDA) such as fetal echogenic bowel or fetal intestinal loop dilatation, nonvisualization of the fetal gallbladder (NVFGB) being rarely observed in isolation. Only 6 cases of CF revealed by isolated NVFGB have been reported so far in the literature. Furthermore, recent studies suggested that this sign is of poor predictive value for CF.
METHODS METHODS
We report on the results of a 6-year French tricenter study on 1,124 cases of fetal USDA for whom a comprehensive molecular study was performed for CF.
RESULTS RESULTS
Among the 37 CF fetuses, 5 (13.5%) presented with isolated NVFGB at ultrasound (US) examination at 24-31 weeks of gestation. This sign was more frequently observed in CF fetuses than in non-CF fetuses, with a likelihood ratio of 2.7. The genotypes included three c.1521_1523del (F508del) homozygous cases and two compound heterozygous cases for a frequent and a rare CF-causing variant.
DISCUSSION CONCLUSIONS
These observations highlight the importance to report on the presence and aspect of the fetal gallbladder at the second trimester US scan and to consider prenatal CFTR molecular analysis in cases of isolated NVFGB.

Identifiants

pubmed: 29920495
pii: 000489120
doi: 10.1159/000489120
doi:

Types de publication

Case Reports Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-316

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Anne Bergougnoux (A)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France, anne.bergougnoux@inserm.fr; caroline.raynal@inserm.fr.
Laboratoire de Génétique de Maladies Rares EA7402, Université de Montpellier, Montpellier, France, anne.bergougnoux@inserm.fr; caroline.raynal@inserm.fr.

Jean-Marie Jouannic (JM)

Service de Médecine Fœtale, Hôpital Armand Trousseau, HUEP, AP-HP, Paris, France.

Fanny Verneau (F)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France.

Thierry Bienvenu (T)

Laboratoire de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, AP-HP, Paris, France.

Natacha Gaitch (N)

Laboratoire de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, AP-HP, Paris, France.

Caroline Raynal (C)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France.

Emmanuelle Girodon (E)

Laboratoire de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, AP-HP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH